The future of anesthesia care.

Transforming Anesthesia Care Through CO₂ Monitoring

A first-of-its-kind oxygen delivery and end-tidal CO₂ monitoring device designed for outpatient sedation, MAC1, TIVA2, and twilight anesthesia. The Aeris™ device improves patient safety, reduces costs, and saves critical time in ambulatory cases. It maximizes the utility of Guedel Oropharyngeal Airways and Nasopharyngeal Airways, airway management devices that currently lack supplemental oxygen delivery and CO₂ monitoring – transforming the hundred million plus of these devices used annually in the U.S. into advanced oxygen delivery and CO₂ monitoring systems – thereby improving the anesthesia providers ability to meet American Society of Anesthesiologists (ASA) guidelines3.

Overcoming Challenges in Outpatient Anesthesia

In outpatient anesthesia, effective oxygen delivery and CO₂ monitoring can be a struggle due to the use of “open systems” like nasal cannulas, oxygen masks, or even the jerry-rigged “tube and tape method4.” Unlike the “closed systems” in general anesthesia, these methods are less reliable.

The Aeris™ device modernizes outpatient anesthesia by providing targeted oxygen delivery and accurate real-time CO₂ monitoring. This ensures higher patient safety and meets the latest ASA guidelines.

Introducing the Aeris™

What the Experts Are Saying. . .

Rene Gonzalez

“The Aeris™ airway management system is a novel device for assisting clinicians in providing and maintaining adequate oxygenation and ventilation during procedures performed under IV sedation.

Its simple but ingenious design delivers oxygen and measures exhaled CO₂ not near the patient’s face (as do oxygen masks), nor to the nares (as do nasal cannulas), but instead provides TARGETED O₂ delivery and capnography more distally, to the pharyngeal/supraglottic region, which is precisely what our objective is during sedation.

It samples CO₂ and delivers O₂ much closer to where they should ideally be measured and delivered.

This targeted delivery system can thus deliver higher FiO2’s to the lower airway at lower O₂ flow rates, as well as much higher quality and reliable continuous capnography waveforms.

And, importantly, it’s very easy and intuitive to use, is seamlessly compatible with current widespread clinical practice techniques, and is in compliance with ASA standards for sedation.

I believe clinicians will welcome and patients will appreciate this new tool in our never-ending goal toward improving patient safety, reducing costs and oxygen waste, and in approaching zero harm to our patients.”

– Rene Gonzalez, MD – former Associate Professor of Anesthesiology and Critical Care Medicine, University of Pittsburgh School of Medicine, former Medical Director, AtlantiCare Ocean County Surgery Center, Inventor of Full Scale Human Patient Medical Training Simulator (now the “SimMan”), Co-author on over 15 Peer-Reviewed Journal Articles – 40+ years of clinical anesthesia experience

Eric Wardrip

“Flexibility, efficiency, and accuracy are combined in the novel Aeris™ device, which provides an easy-to-use way of monitoring end-tidal CO₂ and administering supplemental O₂ during sedation procedures. I foresee the Aeris™ becoming a standard part of my anesthesia practice.”

– Eric Wardrip, MD – Medical Director, SCA Center for Surgery of Encinitas – 40+ years of clinical anesthesia experience

Diana Lugo

“The Aeris™ device is the anesthesia monitoring tool I never knew I needed. It took the guessing and estimating out of my practice when monitoring an anesthetized patient without an endotracheal tube. This device demonstrates superior monitoring to others that administer O₂ while monitoring CO₂. The precise end-tidal CO₂ waveform and quantifiable numeric value remain present throughout the entire case. Additionally, the Aeris™ is easy to use and transformable to accommodate a variety of O₂ administration and CO₂ measuring structures needed for sedation, MAC, TIVA, and twilight anesthetics. The Aeris™ provides confidence that CO₂ monitoring is within ASA guidelines and is a must to be added to every anesthesiologist’s armamentarium.”

– Diana Lugo. DNAP, CRNA – President, Arizona Association of Nurse Anesthesiology

Scott Fimus

“As a practitioner that does over a hundred sedation cases a week this is an essential device for anesthesia practice! The Aeris™ device offers an ideal solution for the makeshift capnography monitoring during sedation cases. Its flexibility, efficiency, and accuracy is truly impressive. A crucial tool for every operating room and sedation site. I predict the Aeris™ device will soon be the standard in sedation cases in anesthesia practice.”

– Scott Fimus, EdD, CRNA – Associate Professor, Midwestern University Nurse Anesthesia Program

Revolutionary Features

Enhanced CO₂ waveform via Aeris™ versus CO₂ waveform via Oxygen Mask with Capnography

Aeris™ capnography waveform

Oxygen Mask with Capnography waveform

Enhanced Oxygen Delivery

The Aeris™ delivers oxygen directly to the pharyngeal/supraglottic region, ensuring high-concentration oxygenation at flow rates as low as 2L/min.

Accurate Real-Time CO₂ Monitoring

The Aeris™ provides precise CO₂ readings and waveforms in real-time. This ensures that healthcare providers have the critical information needed to manage ventilation and sedation levels and respond quickly to patient needs.

Ease Of Use

The Aeris™ intuitively and seamlessly fits into all Guedel Oropharyngeal Airways and Nasopharyngeal Airways and can be used with all capnography monitors.

Improved Patient Safety

The Aeris™ improves patient safety by providing superior oxygen delivery and CO₂ monitoring during outpatient anesthesia. In addition, the Aeris™ minimizes fire risk seen when procedural oxygen masks or nasal cannulas are used. Instead of oxygen pooling around the patient’s head and neck, as occurs with masks and nasal cannulas, the Aeris™ targets oxygen delivery to the patient’s vocal cords, which allows for lower oxygen flow rates to achieve high FiO₂; thereby, minimizing the risk of a spontaneous flammable event.

Cost Savings and Workflow Efficiencies

Less oxygen will be required and a nasal cannula will not have to be cannibalized as is the case with the “tube and tape method”4 when the Aeris™ is used. By allowing the anesthesia provider to titrate sedatives and anesthetics using the capnometry and capnography information provided via the Aeris™, patients can be brought out of sedation at the optimal time to increase patient throughput.

No More Makeshift Solutions

With the Aeris™, healthcare providers no longer need to rely on antiquated devices like nasal cannulas or unreliable makeshift solutions like the “tube and tape” method to deliver oxygen and monitor CO₂. The Aeris™ offers a standardized, reliable approach to airway management by transforming Guedel Oropharyngeal Airways and Nasopharyngeal Airways into novel oxygen delivery and CO₂ monitoring systems.

FAQs

How does the Aeris™ device augment the utility of standard Guedel Oropharyngeal (OPA)⁵ and Nasopharyngeal (NPA) airways during procedural sedation?

The Aeris™ is a novel airway management device that seamlessly inserts into traditional Guedel OPAs and NPAs during procedural sedation to transform such airways into high-performing oxygen (O₂) delivery and end-tidal carbon dioxide (EtCO2) monitoring systems. By providing supplemental O₂ and continuously and reliably monitoring EtCO₂ in real-time, the Aeris™ reduces the risk of hypoxia and allows for early detection of respiratory compromise in sedated patients.

What is the quality of the EtCO₂ waveform produced by the Aeris™?

The CO2 intake port of the Aeris™ is strategically located at the central distal tip of the OPA or NPA, close to the hypopharynx – the optimal location to produce a continuous, reliable, real-time EtCO₂ waveform.

Will the Aeris™ work with existing capnometry hardware?

Yes, the Aeris™is compatible with pre-existing capnography monitors.

How does the use of the Aeris™ impact the workflow of the aesthesia provider?
The Aeris™ comes with a split sampling nasal cannula for pre-oxygenation. The cannula’s capnography/oxygen lines can then be connected to the Aeris™ device to increase workflow efficiency during the medical procedure. The cannula can then be reused in a traditional fashion for post-procedural recovery.
Does the Aeris™ provide equal or better FiO₂ compared to a high-concentration rebreather bag/mask combination?

Not only does the Aeris™ device support FiO₂ levels equal to or better than facemask delivery systems, but the Aeris™ does so at low flow rates (~2L/min) compared to the rates required by masks (~8-15 L/min).

What procedural sedation cases would the Aeris™ provide the most benefit?

Due to the Aeris™ device’s optimal delivery of O₂ and monitoring of EtCO₂, the Aeris™ offers benefits to a wide array of medical procedures and surgeries where outpatient sedation, MAC, TIVA and twilight anesthetics are used. These include but are not limited to:

  • Pain Management Cases
  • Extremity Surgeries
  • Faciomaxillary Surgeries
  • Endoscopic Procedures

 

How does the AERIS™ perform during high O₂ flow rates?

At high O₂ flow rates, the Aeris™ maintains EtCO2 waveform fidelity, a feature not offered by EtCO₂-sampling nasal cannulas, procedural face masks, or the “tube and tape method.”4 This is accomplished by the Aeris™ having the O₂ delivery port and CO₂ intake port offset to minimize the dilution effect O₂ flow has on EtCO₂ detection.

The future is (almost) now!

The Aeris™ anticipates FDA-approval in Q3 of 2025.6

Stay Informed About the Future of Anesthesia Care

Be the first to know about the latest updates and availability of the Aeris™. Join our email list to receive exclusive information on our progress, launch dates, and sample availability.

This field is for validation purposes and should be left unchanged.

Your privacy is of utmost importance to us. We won’t share your email address and will only contact you to send pertinent updates about our Aeris™ device. You can unsubscribe at any time.

What Drives Aeris™

The AERIS™ team consists of successful medical device innovators, esteemed clinicians and researchers, and highly regarded medical device sales and marketing executives. In totality, we have 65 years working in the medical device sector and 60 years of anesthesia care experience, hold 6 patents, have exited 8 medical device companies, and have been responsible for $580M in medical device sales. We are committed to using our experience and passion for medical device innovation and patient care to bring Aeris™ to outpatient clinics where moderate to deep sedation is used across the globe.

Thomas Kotoske, DO, FAOCO, FAACS

AERIS Co-founder & Board Member

Award Winning & Nationally Recognized Cosmetic Surgeon

Paul Fehrenbacher

AERIS CEO & Board Member

Chris Klecher

AERIS Board Member

Senior Vice President, Endoquest Robotics

Eric Wardrip, MD

AERIS Clinical Advisor

Medical Directior, SCA Center for Surgery of Encinitas

Cody Birch, CRNA

AERIS Co-founder & Board Member

Joe Voss

AERIS Director of Sales & Marketing

Stanley Zee

AERIS Board Member

Venture Capitalist, The IDEA Center at The University of Notre Dame

Thomas Kotoske, DO, FAOCO, FAACS

AERIS Co-founder & Board Member

Award Winning & Nationally Recognized Cosmetic Surgeon

Cody Birch, CRNA

AERIS Co-founder & Board Member

Paul Fehrenbacher

AERIS CEO & Board Member

Joe Voss

AERIS Director of Sales & Marketing

Chris Klecher

AERIS Board Member

Senior Vice President, Endoquest Robotics

Stanley Zee

AERIS Board Member

Venture Capitalist, The IDEA Center at The University of Notre Dame

Eric Wardrip, MD

AERIS Clinical Advisor

Medical Directior, SCA Center for Surgery of Encinitas

1MAC (Monitored Anesthesia Care) sedation is a type of anesthesia that provides pain relief and sedation during medial procedures while allowing the patient to remain conscious.

2Total intravenous anesthesia (TIVA) is a general anesthesia technique that uses a combination of intravenous anesthetic agents to induce and maintain anesthesia without inhalational agents.

3The American Society of Anesthesiologists (ASA) has specific guidelines for CO₂ monitoring, particularly during moderate and deep sedation. These guidelines were updated in 2010 and became effective in July 2011. During moderate or deep sedation, the adequacy of ventilation must be evaluated by continual observation of qualitative clinical signs and by monitoring for the presence of exhaled carbon dioxide.

4The “tube and tape method” refers to a common practice used during procedural sedation procedures, particularly in outpatient surgical settings, to monitor a patient’s EtCO₂ levels. A nasal cannula’s O₂ delivery CO₂ sampling tube are cut and taped to an OPA’s opening. This approach is considered a “jerry-rigged” solution, as it is not a standardized or optimal method. The main issues with this method are the tubes often slip out, especially if the patient needs to be moved, and it can provide poor quality EtCO₂ waveforms, resulting in minimal useful data.

5OPA = Guedel Oral Pharyngeal Airway, the most frequently used OPA

6The statements made regarding the Aeris™ device have not been evaluated by the Food and Drug Administration. FDA-approved research has not confirmed the Aers™ devices efficacy.